UK VETERINARY supplies company Novartis Animal Vaccines Ltd has released more details on Pyceze - the new product that has been granted a UK Provisional Marketing Authorisation (PMA) for the treatment and prevention of saprolegnia infection in farmed, fertilised salmonid eggs (FFI, November 2001).
The PMA was the culmination of many years' R&D work. "Pyceze is already approved for use in Norway, Sweden, Finland and Faroes Islands, and is being trialled in Chile, Denmark, North America and Ireland, " says Novartis.
"Work
